New Systolic Heart Failure Study Findings Reported from Suny Downstate Medicine Center (Budget Impact of Adding Ivabradine to Standard of Care in…

Insurance Weekly News

New Systolic Heart Failure Study Findings Reported from Suny Downstate Medicine Center (Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States)

By a News Reporter-Staff News Editor at Insurance Weekly News -- Data detailed on Heart Disorders and Diseases - Systolic Heart Failure have been presented. According to news reporting from New York City, New York, by VerticalNews journalists, research stated, "Heart failure (HF) costs $21 billion annually in direct health care costs, 80% of which is directly attributable to hospitalizations. The SHIFT clinical study demonstrated that ivabradine plus standard of care (SoC) reduced HF-related and all-cause hospitalizations compared with SoC alone."

The news correspondents obtained a quote from the research from Suny Downstate Medicine Center, "To estimate the budget impact of ivabradine from a U.S. commercial payer perspective. A budget impact model estimated the per-member-per month (PMPM) impact of introducing ivabradine to existing formularies by comparing a reference scenario (SoC) and a new drug scenario (ivabradine+SoC) in hypothetical 1 million-member commercial and Medicare Advantage plans. In both scenarios, U.S. claims data were used for the reference cumulative annual rates of hospitalizations (HF, non-HF cardiovascular [CV], and non-CV), and hospitalization rates were adjusted using SHIFT data. The model controlled for mortality risk using SHIFT and U.S. life table data, and hospitalization costs were obtained from U.S. claims data: HF-related=$37,507; non-HF CV=$28,951; and non-CV=$17,904. The annualized wholesale acquisition cost of ivabradine was $4,500, with baseline use for this new drug at 2%, increasing 2% per year. Based on the approved U.S. indication, approximately 2,000 commercially insured patients from a 1 million-member commercial plan were eligible to receive ivabradine. Ivabradine resulted in a PMPM cost savings of $0.01 and $0.04 in years 1 and 3 of the core model, respectively. After including the acquisition price for ivabradine, the model showed a decrease in total costs in the commercial ($991,256 and $474,499, respectively) and Medicare populations ($13,849,262 and $4,280,291, respectively) in year 1. This decrease was driven by ivabradine's reduction in hospitalization rates. For the core model, the estimated pharmacy-only PMPM in year 1 was $0.01 for the commercial population and $0.24 for the Medicare Advantage population. Adding ivabradine to SoC led to lower average annual treatment costs."

According to the news reporters, the research concluded: "The negative PMPM budget impact indicates that ivabradine is an affordable option for U.S. payers."

For more information on this research see: Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States. Journal of Managed Care & Specialty Pharmacy, 2016;22(9):1064-1071. Journal of Managed Care & Specialty Pharmacy can be contacted at: Acad Managed Care Pharmacy, 100 N Pitt St, 400, Alexandria, VA 22314-3134, USA.

Our news journalists report that additional information may be obtained by contacting Downstate Med Center, Ronald & Joan Schiavone Cardiovasc Translat Res I, New York, NY 10128, United States. Additional authors for this research include A.R. Kansal, E.D. Dorman, S. Krotneva, Y. Zheng, H.K. Patel, L. Tavazzi, M. Komajda, I. Ford, M. Bohm and A. Kielhorn.

Keywords for this news article include: New York City, New York, United States, North and Central America, Medicare, Risk and Prevention, Heart Disorders and Diseases, Cardiovascular Diseases, Systolic Heart Failure, Health Policy, Heart Disease, Cardiology, Suny Downstate Medicine Center.